A case with psoriasis-like lesions induced by olmutinib (HM61713) while treating epidermal growth factor receptor T790M mutant advanced lung adenocarcinoma

• Autori principali: Chu-Ju Hung (Autore), Po-Ju Lai (Autore), Jen-Jung Cheng (Autore), Shiow-Jiuan Wey (Autore), Yu-Ping Hsiao (Autore), Ming-Fang Wu (Autore)
• Natura: Libro
• Pubblicazione: Wolters Kluwer Medknow Publications, 2019-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Olmutinib (HM61713) is a third-generation tyrosine kinase inhibitor active against mutant EGFR, including T790M in nonsmall cell lung cancer. The most common side effect of olmutinib to date includes diarrhea, rash, nausea, and pruritus. To the best of our knowledge, it is the first case of psoriasi...